


Oncology
2024-04-10

Antibody-drug conjugates (ADCs) have shown significant efficacy in HER2-positive breast cancer, but the emergence of resistance underscores the need to understand resistance mechanisms. Preclinical models, like the Enhertu-resistant tumor model developed from continuous Enhertu treatment in JIMT-1 tumor tissues in mice, offer insights into resistance mechanisms involving various cellular components within the tumor microenvironment. These models serve as valuable tools for predicting and understanding ADC resistance, aiding in the development of strategies to overcome resistance in clinical settings.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
